Heterogeneity in the costs of type 1 diabetes in a developing country: what are the determining factors?

Diabetes Care in Brazil

BACKGROUND

The diabetes epidemic affects most countries across the world and is increasing at alarming rates in Latin America. Nearly 12 million individuals have diabetes in Brazil, and the current prevalence ranges from 6.3% to 13.5%, depending on the region and the diagnostic criteria adopted in each study.

OBJECTIVE

To provide an overview of diabetes care in Brazil, focusing on studies of diabetes epidemiology, prevalence of patients within the standard targets of care, and economic burden of diabetes and its complications.

METHODS

SciELO and PubMed searches were performed for the terms "diabetes," "Brazil," "Brazilian," and "health system"; relevant literature from 1990 to 2015 was selected. Additional articles identified from reference list searches were also included. All articles selected were published in Portuguese and/or English.

FINDINGS

Recent studies detected a prevalence of gestational diabetes mellitus of nearly 20%. Among patients with type 1 diabetes, almost 90% fail to reach target of glycemic control, with less than 30% receiving treatment for both hypertension and dyslipidemia. More than 75% of patients with type 2 diabetes are either overweight or obese. Most of these patients fail to reach glycemic targets (42.1%) and less than 30% reached the target for systolic and diastolic blood pressure, body mass index, or low-density lipoprotein cholesterol. Only 0.2% of patients reach all these anthropometric and metabolic targets.

CONCLUSIONS

Brazil is the fourth country in the world in number of patients with diabetes. Regardless of the diabetes type, the majority of patients do not meet other metabolic control goals. The economic burden of diabetes and its complications in Brazil is extremely high, and more effective approaches for preventions and management are urgently needed.

Perfil de morbidade e gastos hospitalares com idosos no Paraná, Brasil, entre 2008 e 2012

Resumo: O aumento da população idosa leva a uma crescente demanda por serviços de saúde e expansão dos gastos, com consequências relevantes sobre a estabilidade econômica. Nesse contexto, o objetivo do estudo foi analisar o perfil das morbidades e gastos hospitalares com idosos em relação às condições socioeconômicas e demográficas do Paraná, Brasil, no período de 2008 a 2012, aplicando-se a análise fatorial em componentes principais e de agrupamentos. As regiões com maior e menor desenvolvimento econômico e humano apresentaram alta prevalência das internações e dos custos relativos às doenças do aparelho circulatório, respiratório e do coração para os sexos masculino e feminino. Já nas regiões com nível de desenvolvimento intermediário, as doenças do sistema nervoso em homens e do aparelho circulatório em mulheres se destacaram com relação às morbidades e gastos hospitalares. Assim, ações de prevenção e promoção de saúde a essa população idosa podem ser direcionadas para investigações regionais.

Modern insulins, old paradigms and pragmatism: choosing wisely when deciding how to treat type 1 diabetes

There is a clinical imperative to improve metabolic control in the treatment of patients with type 1 diabetes, but in doing so, hypoglycemia should be avoided at all costs. Insulin analogues and the assumption they would better mimic the pharmacokinetic profile of endogenous insulin secretion emerged as a magic bullet in the treatment of patients with type 1 diabetes. However, although insulin analogues have pharmaceutical properties, such as pharmacodynamic stability, reproducibility of action, and a more physiological timing of action, which could possibly facilitate insulin use, the results obtained in clinical practice have not been as good as expected. Like all clinical decisions, the decision regarding which insulin would be better for the patient should be, if possible, evidence based. Here, we briefly discuss evidence for the use of insulin analogues and the different views with respect to the available evidence that lead to different interpretations and decisions regarding the use of this new technology.